Skip to main content
SpringerLink
Log in

Statin use and female reproductive organ cancer risk in a large population-based setting

  • Original Paper
  • Published:
Cancer Causes & Control Aims and scope Submit manuscript

Abstract

Objective

Statins are an effective and commonly used cholesterol-lowering medication class, but their hypothesized effects on cancer risk remain uncertain. We evaluated the association between statin use and endometrial as well as ovarian cancer risks.

Methods

We conducted a retrospective study with two cohorts of women aged 45–89 years during 1990–2004 within an integrated healthcare delivery system. Information on statin use and covariates were obtained from automated databases. We identified cancer cases through the Surveillance, Epidemiology, and End Results registry. Multivariable Cox proportional hazards models were used to estimate the hazard ratios (HR) and 95% confidence intervals (CI) for incident invasive endometrial and ovarian cancers among statin users compared to nonusers.

Results

Women were followed for a median of about six years. Among 73,336 women studied, 568 endometrial cancer cases were identified. During the study period, 6% of women used statins for at least one year and the median duration of use was 3.1 years. Although not statistically significant, we found a reduction in endometrial cancer risk among statin users (HR = 0.67; 95% CI: 0.39–1.17) compared to nonusers. We identified 326 ovarian cancer cases in a cohort of 93,619 women. There was also a nonsignificant decrease in ovarian cancer risk among statin users (HR = 0.69; 95% CI: 0.32–1.49).

Conclusion

Our study does not support an association between statin use and endometrial as well as ovarian cancers, but a reduced risk cannot be ruled out.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sewester CS, Dombek CE, Olin BR, Kastrup EK, Hebel SK (2004) Drug facts and comparisons. Wolters Kluwer Health, St. Louis

    Google Scholar 

  2. Pharmacy Times (2008) The top 200 prescription drugs of 2006. Available from URL: http://www.pharmacytimes.com/issues/articles/2007-05_4629.asp. Accessed February 21, 2008

  3. Newman TB, Hulley SB (1996) Carcinogenicity of lipid-lowering drugs. JAMA 275:55–60. doi:10.1001/jama.275.1.55

    Article  PubMed  CAS  Google Scholar 

  4. Sacks FM, Pfeffer MA, Moye LA et al (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 335:1001–1009. doi:10.1056/NEJM199610033351401

    Article  PubMed  CAS  Google Scholar 

  5. Shepherd J, Blauw GJ, Murphy MB et al (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360:1623–1630. doi:10.1016/S0140-6736(02)11600-X

    Article  PubMed  CAS  Google Scholar 

  6. Wong WW, Dimitroulakos J, Minden MD, Penn LZ (2002) HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16:508–519. doi:10.1038/sj.leu.2402476

    Article  PubMed  CAS  Google Scholar 

  7. Chan KK, Oza AM, Siu LL (2003) The statins as anticancer agents. Clin Cancer Res 9:10–19

    PubMed  CAS  Google Scholar 

  8. Blais L, Desgagne A, LeLorier J (2000) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case–control study. Arch Intern Med 160:2363–2368. doi:10.1001/archinte.160.15.2363

    Article  PubMed  CAS  Google Scholar 

  9. Kaye JA, Jick H (2004) Statin use and cancer risk in the General Practice Research Database. Br J Cancer 90:635–637. doi:10.1038/sj.bjc.6601566

    Article  PubMed  CAS  Google Scholar 

  10. Coogan PF, Rosenberg L, Strom BL (2007) Statin use and the risk of 10 cancers. Epidemiology 18:213–219. doi:10.1097/01.ede.0000254694.03027.a1

    Article  PubMed  Google Scholar 

  11. Friis S, Poulsen AH, Johnsen SP et al (2005) Cancer risk among statin users: a population-based cohort study. Int J Cancer 114:643–647. doi:10.1002/ijc.20758

    Article  PubMed  CAS  Google Scholar 

  12. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA (2008) Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 17:27–36. doi:10.1002/pds.1507

    Article  PubMed  Google Scholar 

  13. Boudreau DM, Yu O, Miglioretti DL, Buist DS, Heckbert SR, Daling JR (2007) Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol Biomarkers Prev 16:416–421. doi:10.1158/1055-9965.EPI-06-0737

    Article  PubMed  CAS  Google Scholar 

  14. Boudreau DM, Yu O, Buist DS, Miglioretti DL (2008) Statin use and prostate cancer risk in a large population based setting. Cancer Causes Control 19:767–774. doi:10.1007/s10552-008-9139-4

    Article  PubMed  Google Scholar 

  15. Taplin SH, Thompson RS, Schnitzer F, Anderman C, Immanuel V (1990) Revisions in the risk-based breast cancer screening program at Group Health Cooperative. Cancer 66:812–818. doi:10.1002/1097-0142(19900815)66:4<812::AID-CNCR2820660436>3.0.CO;2-1

    Article  PubMed  CAS  Google Scholar 

  16. Saunders KW, Davis RL, Stergachis A (2005) Group health cooperative. In: Strom B (ed) Pharmacoepidemiology, 4th edn. Wiley, Chichester, pp 223–239

    Google Scholar 

  17. Boudreau DM, Doescher MP, Jackson JE, Fishman PA (2004) Impact of healthcare delivery system on where HMO-enrolled seniors purchase medications. Ann Pharmacother 38:1317–1318. doi:10.1345/aph.1D569

    PubMed  Google Scholar 

  18. Buist DS, LaCroix AZ, Brenneman SK, Abbott T (2004) A population-based osteoporosis screening program: who does not participate, and what are the consequences? J Am Geriatr Soc 52:1130–1137. doi:10.1111/j.1532-5415.2004.52311.x

    Article  PubMed  Google Scholar 

  19. Taplin SH, Ichikawa L, Buist DS, Seger D, White E (2004) Evaluating organized breast cancer screening implementation: the prevention of late-stage disease? Cancer Epidemiol Biomarkers Prev 13:225–234. doi:10.1158/1055-9965.EPI-03-0206

    Article  PubMed  Google Scholar 

  20. Washington State Department of Health, Center for Health Statistics (2008) Washington State vital statistics 2005. Available from URL: http://www.doh.wa.gov/ehsphl/chs/chs-data/public/AnnSum_2005.pdf. Accessed February 21, 2008

  21. Newton KM, Wagner EH, Ramsey SD et al (1999) The use of automated data to identify complications and comorbidities of diabetes: a validation study. J Clin Epidemiol 52:199–207. doi:10.1016/S0895-4356(98)00161-9

    Article  PubMed  CAS  Google Scholar 

  22. Hosmer DW Jr, Lemeshow S (1999) Applied survival analysis: regression modeling of time to event data. Wiley, New York

    Google Scholar 

  23. Hastie T, Tibshirani R, Friedman J (eds) (2001) The elements of statistical learning; data mining, inference, and prediction. Springer, New York

    Google Scholar 

  24. Coogan P, Rosenberg L, Strom B (2007) Statins and cancer. Epidemiology 18:520–521. doi:10.1097/EDE.0b013e3180646718

    Article  Google Scholar 

  25. Friedlander M, de Souza P, Segelov E (1992) Risk factors, epidemiology, screening, and prognostic factors in female genital cancer. Curr Opin Oncol 4:913–922. doi:10.1097/00001622-199210000-00016

    Article  PubMed  CAS  Google Scholar 

  26. Duncan RE, El-Sohemy A, Archer MC (2005) Statins and cancer development. Cancer Epidemiol Biomarkers Prev 14:1897–1898. doi:10.1158/1055-9965.EPI-05-0027

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank Deborah Seger for her valuable contributions in computing. This study was supported by NCI grant numbers CA108357 and CA63731.

Author information

Authors and Affiliations

  1. Group Health Center for Health Studies, 1730 Minor Ave., Suite 1600, Seattle, WA, 98101, USA

    Onchee Yu, Denise M. Boudreau, Diana S. M. Buist & Diana L. Miglioretti

  2. University of Washington, Seattle, WA, USA

    Denise M. Boudreau, Diana S. M. Buist & Diana L. Miglioretti

  3. Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    Diana S. M. Buist

Authors
  1. Onchee Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Denise M. Boudreau
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Diana S. M. Buist
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Diana L. Miglioretti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Onchee Yu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yu, O., Boudreau, D.M., Buist, D.S.M. et al. Statin use and female reproductive organ cancer risk in a large population-based setting. Cancer Causes Control 20, 609–616 (2009). https://doi.org/10.1007/s10552-008-9271-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10552-008-9271-1

Keywords

Search

Navigation